Levon Larents

DIAGNOS Gets the Green Light for the Use of its Diabetic Retinopathy Screening Technology in Quebec Hospitals

Retrieved on: 
Tuesday, January 31, 2023
Blockchain.com, Health, Diabetes, COVID-19, Diabetic retinopathy, Severe cognitive impairment, Hospital, Artificial intelligence, Patient, Statistics Canada, ADK, Levon Larents, Health insurance, Pharmaceutical industry, Ophthalmology, Endocrinology

This report has been disseminated to all hospitals in the province, highlighting the cost savings and other benefits of implementing DIAGNOS' technology.

Key Points: 
  • This report has been disseminated to all hospitals in the province, highlighting the cost savings and other benefits of implementing DIAGNOS' technology.
  • We are overjoyed by the government’s acknowledgement of the value of our AI-based Diabetic Retinopathy screening solution.
  • DIAGNOS will now begin commercializing it to all hospitals and clinics in the province," says Mr. AndrĂ© Larente, President of DIAGNOS.
  • With such a large population of diabetic patients receiving endocrinology services at Quebec hospitals, the market potential for DIAGNOS' AI screening solutions is significant.

Diagnos A.I. retinal screening technology expands into international markets

Retrieved on: 
Thursday, August 5, 2021
Efficiency, Industry, ADK, Optometry, Multimedia, Eye, Toronto Stock Exchange, Severe cognitive impairment, Hospital, Algorithm, Chum, Artificial intelligence, Ai, Retina, Jody Vance, Capillary, Federal Commission for the Protection against Sanitary Risk, Diabetes, EC, Food and Drug Administration, Clinic, FRA, Solution, Anomaly, Population, Technology, Vein, Levon Larents, Cara, Medicine, Stroke, Partnership, Artery, Health Canada, Aneurysm, BCI, Patient safety, Adoption, Atherosclerosis, Blockade IMARC, Patient, Bleeding, AV, Risk, Adult, Iris, Disease, Drug, Medical device, Medical imaging, Telescopic sight, Cryptocurrency, Pharmaceutical industry

CARA's artificial intelligence-based image enhancement algorithms provide sharper, clearer, retinal images that can then be analyzed for anomalies.

Key Points: 
  • CARA's artificial intelligence-based image enhancement algorithms provide sharper, clearer, retinal images that can then be analyzed for anomalies.
  • "IRIS continues to be at the forefront of implementing technology driven solutions for clinical optometry and optical retail," stated said Eric Babin, President of IRIS.
  • "Artificial intelligence will raise our standard when it comes to quality of care and we are eager to collaborate with Diagnos."
  • Diagnos' technology can inform a patient that she is at risk for a heart attack or stroke.